Story perspectives

FDA Expedites Biosimilar Approvals Amid Price Concerns

11/16/2025

49 5

Summary

Story summary

The FDA plans to expedite biosimilar approvals to boost competition and lower prices.
Experts caution prices may not fall quickly despite these efforts.
Biologics such as insulin remain costly due to complex production.
Biosimilars can reduce costs by 15% to 35%.
U.S. President Donald Trump's administration proposes changes that may not significantly lower prices because many patients face high out-of-pocket costs and patent disputes slow market entry.

1 of 1

Story summary

The FDA plans to expedite biosimilar approvals to boost competition and lower prices.
Experts caution prices may not fall quickly despite these efforts.
Biologics such as insulin remain costly due to complex production.
Biosimilars can reduce costs by 15% to 35%.
U.S. President Donald Trump's administration proposes changes that may not significantly lower prices because many patients face high out-of-pocket costs and patent disputes slow market entry.